Online Appendix for the following JACC article
TITLE: New P2Y12 Inhibitors Versus Clopidogrel in Percutaneous Coronary
Intervention: A Meta-analysis
AUTHORS: Anne Bellemain-Appaix, MD, David Brieger, MD, PHD, Farzin Beygui,
MD, PHD, Johanne Silvain, MD, Ana Pena, PHD, Guillaume Cayla, MD, Olivier
Barthélémy, MD, Jean-Philippe Collet, MD, PHD, Gilles Montalescot, MD, PHD
APPENDIX
I2 test for heterogeneity between studies
Global
Analysis
All PCI Analysis
STEMI
Analysis
PCI for STEMI
Death
p = 0.67
I2 = 0%,
95% CI: 0%-54%
p = 0.75
I2 = 0%,
95% CI: 0%-53%
p = 0.78
I2 = 0%,
95% CI: 0%-57%
p = 0.78
I2 = 0%,
95% CI: 0%-57%
CV death
p = 0.78
I2 = 0%,
95% CI: 0%-53%
p = 0.85
I2 = 0%,
95% CI: 0%-38%
p = 0.87
I2 = 0%,
95% CI: 0%-26%
p = 0.78
I2 = 0%,
95% CI: 0%-58%
MACEs
p = 0.34
I2 = 12%,
95% CI: 0%-71%
p = 0.17
I2 = 36%,
95% CI: 0%-74%
p = 0.91
I2 = 0%,
95% CI: 0%-13%
p = 0.96
I2 = 0%,
95% CI: 0%-0%
MI
p = 0.03
I2 = 55%,
95% CI: 0%-80%
p = 0.009
I2 = 67%,
95% CI: 23%-86%
p = 0.54
I2 = 0%,
95% CI: 0%-79%
p = 0.48
I2 = 0%,
95% CI: 0%-81%
Stent thrombosis
p = 0.08
I2 = 49%,
95% CI: 0%-80%
p = 0.06
I2 = 55%,
95% CI: 0%-83%
p = 0.79
I2 = 0%,
95% CI: 0%-56%
p = 0.77
I2 = 0%,
95% CI: 0%-59%
Stroke
p = 0.98
I2 = 0%,
95% CI: 0%-0%
p = 0.93
I2 = 0%,
95% CI: 0%-5%
p = 0.39
I2 = 0%,
95% CI: 0%-89%
p = 0.60
I2 = 0%,
C 95% [0%-80%
Major bleeding
p = 0.44
I2 = 0%,
95% CI: 0%-67%
p = 0.41
I2 = 2%,
95% CI: 0%-75%
p = 0.53
I2 = 0%,
95% CI: 0%-84%
p = 0.16
I2 = 46%,
95% CI: 0%-84%
Major or minor
bleeding
p = 0.24
I2 = 24%,
95% CI: 0%-65%
p = 0.63
I2 = 0%,
95% CI: 0%-64%
p = 0.25
I2 = 25%,
IC not calculable
p = 0.14
I2 = 54%,
IC not calculable
End Point
Flow Chart References
1.
Berger JS, Roe MT, Gibson CM, et al. Safety and feasibility of adjunctive
antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible
P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in
patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of
platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion
in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J 2009;158:9981004 e1.
2.
Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with
cangrelor during PCI. N Engl J Med 2009;361:2330-41.
3.
Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial
efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor
antagonist, compared with clopidogrel, in patients with non-ST-segment elevation
acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll
Cardiol 2007;50:1844-51.
4.
Collet JP, Silvain J, Landivier A, et al. Dose effect of clopidogrel reloading in
patients already on 75-mg maintenance dose: the Reload with Clopidogrel
Before Coronary Angioplasty in Subjects Treated Long Term with Dual
Antiplatelet Therapy (RELOAD) study. Circulation 2008;118:1225-33.
5.
Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of
clopidogrel on platelet reactivity and clinical outcomes in patients with non-STsegment elevation acute coronary syndrome undergoing coronary stenting. J Am
Coll Cardiol 2006;48:1339-45.
6.
Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous
P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary
intervention: results from a 2-part, phase II, multicenter, randomized, placeboand active-controlled trial. Am Heart J 2006;151:689 e1-689 e10.
7.
Greenbaum AB, Ohman EM, Gibson CM, et al. Preliminary experience with
intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose
alteplase during acute myocardial infarction: results of the Safety, Tolerability and
Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.
Am Heart J 2007;154:702-9.
8.
Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel
loading with eptifibatide to arrest the reactivity of platelets: results of the
Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR
PLATELETS) study. Circulation 2005;111:1153-9.
9.
Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in
patients undergoing PCI. N Engl J Med 2009;361:2318-29.
10.
Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G.
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12
antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind
comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47.
11.
Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of
platelet aggregation and a lower rate of non-responders compared with
clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur
Heart J 2006;27:1166-73.
12.
Lemesle G, Delhaye C, Sudre A, et al. Impact of high loading and maintenance
dose of clopidogrel within the first 15 days after percutaneous coronary
intervention on patient outcome. Am Heart J 2009;157:375-82.
13.
Mehta SR, Bassand JP, Chrolavicius S, et al. Design and rationale of
CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing
strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation
acute coronary syndromes managed with an early invasive strategy. Am Heart J
2008;156:1080-1088 e1.
14.
Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high
clopidogrel loading doses in patients with non-ST-segment elevation acute
coronary syndromes: the ALBION (Assessment of the Best Loading Dose of
Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial.
J Am Coll Cardiol 2006;48:931-8.
15.
Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with
clopidogrel in patients undergoing percutaneous coronary intervention for STelevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised
controlled trial. Lancet 2009;373:723-31.
16.
Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine
prasugrel compared with clopidogrel on spontaneous and procedural myocardial
infarction in the Trial to Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial
Infarction 38: an application of the classification system from the universal
definition of myocardial infarction. Circulation 2009;119:2758-64.
17.
Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G.
Randomized trial of high loading dose of clopidogrel for reduction of
periprocedural myocardial infarction in patients undergoing coronary intervention:
results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial
Damage during Angioplasty) study. Circulation 2005;111:2099-106.
18.
Pride YB, Wiviott SD, Buros JL, et al. Effect of prasugrel versus clopidogrel on
outcomes among patients with acute coronary syndrome undergoing
percutaneous coronary intervention without stent implantation: a TRial to assess
Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with
prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Am Heart J 2009;158:e21-6.
19.
Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by
AZD6140, a reversible oral P2Y12 receptor antagonist, compared with
clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol
2007;50:1852-6.
20.
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients
with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
21.
Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster
P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient
generation of its active metabolite in aspirin-treated patients with coronary artery
disease. Eur Heart J 2008;29:21-30.
22.
Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel
(CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel
in percutaneous coronary intervention: results of the Joint Utilization of
Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation
2005;111:3366-73.
23.
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in
patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
24.
Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loadingand maintenance-dose clopidogrel in patients with planned percutaneous
coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of
Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Circulation 2007;116:2923-32.
25.
Wolfram RM, Torguson RL, Hassani SE, et al. Clopidogrel loading dose (300
versus 600 mg) strategies for patients with stable angina pectoris subjected to
percutaneous coronary intervention. Am J Cardiol 2006;97:984-9.
26.
Steg G, James S, Harrington R, et al. Ticagrelor compared with clopidogrel in
patients with acute coronary syndromes : the PLATelet Inhibition and patient
Outcomes trial; Outcomes in patients with STEMI and planned PCI, in press
27.
Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with
clopidogrel in patients with a planned invasive strategy for acute coronary
syndromes (PLATO): a randomised double-blind study. Lancet.
28.
Mehta S. Results of the CURRENT-OASIS 7 STEMI PCI. TCT 2009; September
24, 2009; San Francisco, CA.